Handelsavisen
prelaunch
Companies Healthcare SPEA.BO
SP
SPEA.BO BSE (India) Pharmaceuticals

Spea.Bo

$269,85
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
15,3 %
ROE
23,5 %
Net margin
12,3 %
Debt / equity
0,16
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

SPEA.BO operates in the Pharmaceuticals & Medical Research industry, focusing on the development and commercialization of pharmaceutical products and medical research solutions.

Business. SPEA.BO operates in the Pharmaceuticals & Medical Research industry, focusing on the development and commercialization of pharmaceutical products and medical research solutions.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
23,5 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning SPEA.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to SPEA.BO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    SPEA.BO operates in the Pharmaceuticals & Medical Research industry, focusing on the development and commercialization of pharmaceutical products and medical research solutions.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    SPEA.BO maintains a strong liquidity position, as evidenced by a current ratio of 5.5, indicating that the company has sufficient current assets to cover its current liabilities multiple times over. However, the company reported a negative operating cash flow of -64,320,000 INR, which may signal short-term cash flow challenges despite its high current ratio. The debt-to-equity ratio of 0.16 suggests a conservative capital structure, with a relatively low proportion of debt compared to equity, which reduces financial risk.

    In terms of profitability, SPEA.BO demonstrates a return on equity (ROE) of 23.5% and a return on assets (ROA) of 17.98%, both of which are strong indicators of efficient use of equity and assets to generate profit. These figures are well above the typical thresholds for the pharmaceutical industry, suggesting that the company is outperforming its peers in terms of profitability.

    The company's revenue is concentrated in a single segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration may expose the company to higher risks if the segment or region experiences a downturn. The lack of geographic diversification is a notable concern, as it limits the company's ability to mitigate regional economic fluctuations.

    Looking at the growth trajectory, SPEA.BO has shown a consistent increase in revenue, with a total revenue of 582,714,000 INR. While the company has not provided specific outlook figures for the next fiscal year, the current financial performance suggests a positive trend. The capital expenditure of -6,071,000 INR indicates that the company is investing in its operations, which could support future growth.

    The risk assessment for SPEA.BO highlights a medium liquidity risk, primarily due to the negative operating cash flow. The company also faces a low dilution risk, as there is no indication of significant share issuance or dilution in the near term. The key flag of net cash being negative after subtracting total debt is a concern, as it may affect the company's ability to meet its short-term obligations.

    Recent events and filings do not indicate any major changes in the company's operations or financial strategy. The company's financial statements and disclosures have not revealed any significant legal or regulatory issues that could impact its operations. The absence of recent major events suggests a stable operational environment for SPEA.BO.

    Key takeaways
    • SPEA.BO has a strong liquidity position with a current ratio of 5.5, indicating sufficient current assets to cover liabilities.
    • The company's profitability is robust, with a return on equity of 23.5% and a return on assets of 17.98%.
    • Revenue is concentrated in a single segment, which may increase risk exposure.
    • The company is investing in its operations, as indicated by a capital expenditure of -6,071,000 INR.
    • SPEA.BO faces a medium liquidity risk due to a negative operating cash flow.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $269,85
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $306.2M
    Net cash
    -$50.5M
    Current ratio
    5.5
    Debt / equity
    0.2
    ROA
    18.0%
    ROE
    23.5%
    Cash conversion
    -89.0%
    CapEx / revenue
    -1.0%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin15,3 %Above P75
    Net Margin12,3 %Above median
    ROE23,5 %Best in class
    Capex / Rev-1,0 %Above P75
    D/E0,16Above median
    Cash Conv-0,89Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • SPEA.BO Market data — financials · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    SPEA.BOCanonical
    BSE (India) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage